Talapro-1: Phase Ii Study Of Talazoparib (Tala) In Patients (Pts) With Dna Damage Repair Alterations (Ddrm) And Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

JS De Bono,N Mehra, CS Higano,F Saad,C Buttigliero, IM van Oort

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 11|浏览4

暂无评分

摘要

93Background: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) show antitumor activity in mCRPC/DDRm pts treated with novel hormonal therapy (NHT). TALAPRO-1 is an open-label study evaluating ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要